BackNextGen Healthcare Overview

NextGen Healthcare Other Current Liabilities

Latest other current liabilities for NXGN: $77M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$76.87M
50.79% YoYΔ $-79.33M vs prior year quarter

Peer trimmed avg / median

Loading

NextGen Healthcare Other Current Liabilities History

Loading

NextGen Healthcare vs. peers: Other Current Liabilities Comparison

Loading

NextGen Healthcare Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NextGen Healthcare (NXGN) FAQ

NextGen Healthcare's other current liabilities stands at $77M as of September 2023. That compares with $160M in the prior-year period — down 50.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NextGen Healthcare reported $77M in other current liabilities versus $160M a year earlier — a 50.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $160M in the prior-year period — down 50.8% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NextGen Healthcare's other current liabilities evolved across reporting periods, while the comparison chart places NXGN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Technology, other current liabilities is commonly used to spot outliers. NextGen Healthcare's reading of $77M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.